Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Comorbidity Index Predicts Transplant Outcomes
Biol Blood Marrow Transplant; ePub 2016 Oct 24; Barba, et al
The HCT-Comorbidity Index I and age-adjusted HCT-CI (HCT-CI/age) can predict transplant outcomes in CD34-selected allo-HCT candidates, according to an analysis involving 346 individuals.
Participants had acute myeloid leukemia or myelodysplastic syndrome. Investigators looked at the relationship between HCT-CI, the recently developed HCT-CI/age, and transplant outcomes. Among the results:
- Median HCT-CI score was 2, and HCT-CI/age score was 3.
- Higher scores were linked with higher non-relapse mortality (NRM) and lower overall survival.
- With HCT-CI/age, there was a progressive increase in NRM and decrease in overall survival with increasing scores in all 4 risk groups.
- Higher scores in both models were linked with lower chronic graft-versus-host disease relapse-free survival, but not with higher relapse.
- Both models were able to accurately predict NRM.
Barba P, Ratan R, Cho C, et al. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts outcomes in patients with acute myeloid leukemia and myelodysplastic syndromes receiving CD34+ selected grafts for allogeneic hematopoietic cell transplantation. [Published online ahead of print October 24, 2016]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2016.10.017.